Business
Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease
T-Detect Lyme enables patients and healthcare providers to detect early Lyme disease with greater sensitivity than leading antibody tests SEATTLE, June 15,
About this update from Adaptive Biotechnologies Corporation
[{"type":"text","content":"T-Detect Lyme enables patients and healthcare providers to detect early Lyme disease with greater sensitivity than leading antibody tests\nSEATTLE, June 15, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of T-Detect™ Lyme. This is the company’s second test to be made available from its growing T-Detect franchise. The T-Detect test detects an immune response by leveraging the body’s unique T-cell response to disease-associated antigens. T-Detect Lyme identifies T cells activated by Borrelia burgdorferi, the bacterium that causes Lyme disease, to help diagnose early Lyme disease. T-Detect Lyme, administered as a simple blood test, is intended to aid in the diagnosis of early Lyme disease in adult patients demonstrating signs and symptoms. These symptoms include, but are not limited to, the presence of an Erythema migrans (EM) rash, fever, chills, headache, fatigue, muscle and joint aches, and swollen lymph nodes. “The T-Detect franchise leverages the immune system’s natural abilities and the exquisite specificity of T cells to detect disease early. The availability of T-Detect Lyme may help shorten the time to accurate diagnosis for patients with early Lyme disease. Also, the addition of T-Detect Lyme will support scaling clinical operations to enable our growing T-Detect portfolio, including testing in autoimmune disorders with high unmet need,” said Sharon Benzeno, Ph.D., chief commercial officer, immune medicine, Adaptive Biotechnologies. “T-Detect Lyme has demonstrated greater sensitivity than serology in early Lyme disease and may aid in the early diagnosis of up to two times more cases that may be missed by traditional serology testing. We aim to further improve the test sensitivity over time using new data sets from additional individuals to be able to help more patients.” In the U.S., Lyme disease is the most common tick-borne illness, with approximately half a million newly infected people per year.1 An early diagnosis of Lyme disease facilitates treatment initiation to stop disease progression. However, today’s standard antibody tests may miss up to 75% of Lyme disease cases in the acute, or early, phase o...